Business Wire·Nov 10, 2026, 5:15 PM ET

Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo

Rallybio Corporation announced a one-for-two reverse stock split of its common stock to facilitate the merger with Avenzo Therapeutics.
The split ratio was approved by stockholders on November 4, 2026, & finalized by the Board of Directors with Avenzo's agreement on November 8, 2026.
The reverse split is expected to become effective at 12:01 a.m. Eastern Time on November 20, 2026, prior to the anticipated merger completion.
Every two shares of Rallybio common stock will be combined into one share, reducing the total issued shares from approximately 5.6 million to 2.8 million.
Following the merger & Nasdaq approvals, Rallybio plans to change its name to Avenzo Therapeutics, Inc. & trade under the symbol "AVZO".
No fractional shares will be issued; stockholders entitled to fractions will receive cash payments based on the closing price on the effective date.
Proportionate adjustments will be made to outstanding pre-funded warrants, equity awards, & share reserves in accordance with their respective terms.
Computershare Trust Company, N.A. is acting as the exchange agent & transfer agent for the transaction.
Avenzo Therapeutics is a clinical-stage oncology company with pipeline candidates including AVZO-021, AVZO-023, AVZO-1418, & AVZO-103.
Rallybio is a clinical-stage biotechnology company focused on therapies for severe & rare diseases involving complement dysregulation & hematology.